# Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

> **NCT05312671** · PHASE2 · RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 63 (estimated)

## Conditions studied

- Small Cell Neuroendocrine Carcinoma of Bladder
- Bladder Cancer
- Urothelial Carcinoma Bladder

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Etoposide
- **PROCEDURE:** Cystectomy

## Key facts

- **NCT ID:** NCT05312671
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-27
- **Primary completion:** 2027-10
- **Final completion:** 2029-10
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2025-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05312671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05312671, "Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05312671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*